Analysts anticipate Geovax Labs to report an earnings per share (EPS) of $-0.95. Investors in Geovax Labs are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and ...

EQS-News: GeoVax, Inc. / Key word (s): Financial GeoVax Labs Announces $4.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules 24.03.2025 / 13:05 CET/CEST The issuer is ...

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a ...

We have seen 11 institutional investors add shares of GEOVAX LABS stock to their portfolio, and 11 decrease their positions in their most recent quarter.

GeoVax Labs (NASDAQ: GOVX) is currently a micro-cap biotech stock that multiple Wall Street analysts see massive potential ...

Boral Capital says GeoVax Labs (GOVX)’ GEO-MVA vaccine ... and streamline your search for investment opportunities with TipRanks’ Stock Screener. Published first on TheFly – the ultimate ...

Shares of GeoVax Labs, Inc. (NASDAQ:GOVX – Get Free Report) have received an average recommendation of “Buy” from the seven ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel ...